Mydecine Innovations Group Stock Today
| MYCOF Stock | USD 0.01 0.01 125.00% |
PerformanceGood
| Odds Of DistressQuite High
|
Mydecine Innovations is trading at 0.009 as of the 23rd of March 2025. This is a 125.00 percent increase since the beginning of the trading day. The stock's lowest day price was 0.009. Mydecine Innovations has more than 66 % chance of experiencing financial distress in the next few years of operation. However, it had a very good returns during the last 90 days. The performance scores are derived for the period starting the 23rd of December 2024 and ending today, the 23rd of March 2025. Click here to learn more.
Mydecine Innovations Group Inc., a biotech and life sciences company, engages in the development and commercialization of drugs for treating mental health problems. Mydecine Innovations Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada. The company has 13.01 M outstanding shares. More on Mydecine Innovations Group
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Mydecine Pink Sheet Highlights
| Business Concentration | Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) |
Mydecine Innovations Group [MYCOF] is a Pink Sheet which is traded between brokers as part of OTC trading. The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.94 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Mydecine Innovations's market, we take the total number of its shares issued and multiply it by Mydecine Innovations's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Mydecine Innovations classifies itself under Healthcare sector and is part of Drug Manufacturers—Specialty & Generic industry. The entity has 13.01 M outstanding shares.
Mydecine Innovations Group has accumulated about 324.15 K in cash with (24.05 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.04, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Mydecine Innovations Probability Of Bankruptcy
Ownership AllocationMydecine Innovations Group secures 8.71 % of its outstanding shares held by insiders and 0.0 % owned by institutional investors.
Check Mydecine Ownership Details
Mydecine Innovations Risk Profiles
| Mean Deviation | 23.85 | |||
| Semi Deviation | 19.03 | |||
| Standard Deviation | 34.6 | |||
| Variance | 1197.42 |
Mydecine Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Mydecine Innovations without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Risk-Return Analysis Now
Risk-Return AnalysisView associations between returns expected from investment and the risk you assume |
| All Next | Launch Module |
Mydecine Innovations Corporate Management
| Sanford Stein | Gen Officer | Profile | |
| Damon Michaels | CoFounder COO | Profile | |
| Robert MA | Chief CoFounder | Profile | |
| William Cook | Interim Inc | Profile | |
| Morgan Kervitsky | Director Marketing | Profile | |
| Michel Rudolphie | Pres Operations | Profile | |
| David Bartch | CEO, CoFounder | Profile |
Other Information on Investing in Mydecine Pink Sheet
Mydecine Innovations financial ratios help investors to determine whether Mydecine Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Mydecine with respect to the benefits of owning Mydecine Innovations security.